Group 1 Antineoplastic drugs, including those with the manufacturer’s safe-handling guidance (MSHG) |
Group 2 Non-antineoplastic drugs that meet one or more of the NIOSH criteria for a hazardous drug, including those with the manufacturer’s safe-handling guidance (MSHG) |
Group 3 Non-antineoplastic drugs that primarily have adverse reproductive effects |
|
abacavir-dolutegravir-lamivudine |